Search

everythinglearnresearchcommunity

for

Search:↓

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Lamotrigine can cause hair loss in some patients.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Glibenclamide slows breast cancer cell growth by stopping cell division.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

New compounds may help treat prostate cancer by reducing cell growth.

Erlotinib can cause nonscarring hair loss and itchy skin.

A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.

Pexidartinib often causes liver issues and fatigue, especially in women.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.